Brain cancer patients get continued access to promising combo therapy in long-term safety study

NCT ID NCT07569042

Recruiting now Disease control Sponsor: Novelwise Pharmaceutical Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to an experimental drug (NBM-BMX) plus standard chemotherapy (temozolomide) for people with newly diagnosed glioblastoma, a serious brain cancer, who completed a previous trial. About 15 participants will be monitored for long-term safety and how well the treatment controls the disease. The goal is to see if the combination remains safe and helps keep the cancer from growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM OF BRAIN

Contacts and locations

Locations

Kaohsiung Medical University Chung-Ho Memorial Hospital
NOT_YET_RECRUITING

Kaohsiung City, 807, Taiwan
Linkou Chang-Gung Memorial Hospital
RECRUITING

Taoyuan City, 333, Taiwan
Taichung Veterans General Hospital
NOT_YET_RECRUITING

Taichung, 407, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.